What is the Purpose of this Study?
The purpose of this study is to determine the safest and most effective dose of an experimental drug called INCA33890 in people with selected advanced or metastatic solid tumors. INCA33890 is an immune therapy (drug designed to help the immune system become more active and possibly fight cancer). It is a bispecific antibody, which is a specific type of antibody (protein that fights infection) made in a laboratory that has the ability to bind at the same time to 2 different types of molecule targets. Therefore, it can attach to specific cells in the body and affect their function. This study will evaluate the safety of INCA33890 and how the patient’s cancer reacts to it, as well as the highest dose of the drug that patients can take with the fewest side effects. Researchers will then examine the safety of INCA33890 at the chosen doses and the effects it has on the patient’s cancer, if any.
Eligibility
- * ≥18 years old
- * Histologically or cytologically confirmed advanced or metastatic malignancies
- * Participants must have experienced disease progression after treatment with available therapies, including anti-PD-(L)1 or anti-CTLA4 therapy if applicable, that are known to confer clinical benefit, or who are intolerant to, or ineligible for standard treatment. Prior anti-PD-(L)1 therapy should not have been discontinued because of intolerance.
- * ECOG performance status score of 0 or 1.
Where can I participate?
Cedars-Sinai Cancer at The Angeles Clinic and Research Institute
More about this Clinical Trial
What is the full name of this clinical trial?
INCA33890101: A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors